Display options
Cite
Carvalho A, Cunha C, Iannitti RG, et al. Host defense pathways against fungi: the basis for vaccines and immunotherapy. Front Microbiol. 2012;3:176doi: 10.3389/fmicb.2012.00176.
Carvalho, A., Cunha, C., Iannitti, R. G., Casagrande, A., Bistoni, F., Aversa, F., & Romani, L. (2012). Host defense pathways against fungi: the basis for vaccines and immunotherapy. Frontiers in microbiology, 3176. https://doi.org/10.3389/fmicb.2012.00176
Carvalho, Agostinho, et al. "Host defense pathways against fungi: the basis for vaccines and immunotherapy." Frontiers in microbiology vol. 3 (2012): 176. doi: https://doi.org/10.3389/fmicb.2012.00176
Carvalho A, Cunha C, Iannitti RG, Casagrande A, Bistoni F, Aversa F, Romani L. Host defense pathways against fungi: the basis for vaccines and immunotherapy. Front Microbiol. 2012 May 10;3:176. doi: 10.3389/fmicb.2012.00176. eCollection 2012. PMID: 22590466; PMCID: PMC3349272.
Copy Download .nbib Format: NLM
Share it on

Front Microbiol. 2012 May 10;3:176. doi: 10.3389/fmicb.2012.00176. eCollection 2012.

Host defense pathways against fungi: the basis for vaccines and immunotherapy.

Frontiers in microbiology

Agostinho Carvalho, Cristina Cunha, Rossana G Iannitti, Andrea Casagrande, Francesco Bistoni, Franco Aversa, Luigina Romani

Affiliations

  1. Department of Experimental Medicine and Biochemical Sciences, University of Perugia Perugia, Italy.

PMID: 22590466 PMCID: PMC3349272 DOI: 10.3389/fmicb.2012.00176

Abstract

Fungal vaccines have long been a goal in the fields of immunology and microbiology to counter the high mortality and morbidity rates owing to fungal diseases, particularly in immunocompromised patients. However, the design of effective vaccination formulations for durable protection to the different fungi has lagged behind due to the important differences among fungi and their biology and our limited understanding of the complex host-pathogen interactions and immune responses. Overcoming these challenges is expected to contribute to improved vaccination strategies aimed at personalized efficacy across distinct target patient populations. This likely requires the integration of multifaceted approaches encompassing advanced immunology, systems biology, immunogenetics, and bioinformatics in the fields of fungal and host biology and their reciprocal interactions.

Keywords: fungi; immune responses; immunotherapy; vaccines; vaccinomics

References

  1. J Immunol. 2008 Jan 15;180(2):1088-97 - PubMed
  2. Vaccine. 2010 Mar 19;28(14):2615-23 - PubMed
  3. N Engl J Med. 2009 Apr 30;360(18):1870-84 - PubMed
  4. Nat Rev Microbiol. 2007 Jan;5(1):13-28 - PubMed
  5. Infect Immun. 2008 Sep;76(9):4214-21 - PubMed
  6. J Clin Invest. 2012 May;122(5):1816-31 - PubMed
  7. J Clin Invest. 2011 Feb;121(2):554-68 - PubMed
  8. Nat Rev Microbiol. 2003 Oct;1(1):17-24 - PubMed
  9. Expert Rev Anti Infect Ther. 2012 Mar;10(3):257-9 - PubMed
  10. Blood. 2012 Jan 26;119(4):967-77 - PubMed
  11. Infect Immun. 2007 Nov;75(11):5085-94 - PubMed
  12. Cell. 2012 Mar 16;148(6):1284-92 - PubMed
  13. J Exp Med. 2003 Jun 2;197(11):1405-16 - PubMed
  14. Mucosal Immunol. 2009 Jul;2(4):362-74 - PubMed
  15. Immunity. 2010 Oct 29;33(4):516-29 - PubMed
  16. Cell Host Microbe. 2011 Nov 17;10(5):437-50 - PubMed
  17. J Immunol. 2006 Nov 1;177(9):5811-8 - PubMed
  18. Int J Infect Dis. 2010 Jun;14(6):e460-8 - PubMed
  19. Immunity. 2012 Jan 27;36(1):68-78 - PubMed
  20. Nat Rev Immunol. 2011 Apr;11(4):275-88 - PubMed
  21. J Immunol. 2005 Dec 1;175(11):7496-503 - PubMed
  22. J Immunol. 2000 Jul 1;165(1):381-8 - PubMed
  23. Nat Immunol. 2011 Dec 16;13(1):21-8 - PubMed
  24. Infect Immun. 2006 Sep;74(9):5075-84 - PubMed
  25. Vaccine. 2006 Jul 26;24(31-32):5904-11 - PubMed
  26. J Clin Invest. 2012 Mar;122(3):987-99 - PubMed
  27. Blood. 2011 Jun 2;117(22):5881-91 - PubMed
  28. Cell Host Microbe. 2011 Oct 20;10(4):311-23 - PubMed
  29. Clin Microbiol Infect. 2012 Feb;18(2):120-5 - PubMed
  30. Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13526-31 - PubMed
  31. J Immunol. 2009 Jul 15;183(2):1279-90 - PubMed
  32. Immunity. 2010 Oct 29;33(4):451-63 - PubMed
  33. N Engl J Med. 2003 Oct 2;349(14):1341-8 - PubMed
  34. mBio. 2010 May 18;1(1): - PubMed
  35. Nat Rev Immunol. 2008 Nov;8(11):889-95 - PubMed
  36. Trends Microbiol. 2006 Apr;14(4):183-9 - PubMed
  37. Antimicrob Agents Chemother. 2003 Jul;47(7):2208-16 - PubMed
  38. Vaccine. 2010 Apr 30;28(20):3509-10 - PubMed
  39. Infect Immun. 2011 Jun;79(6):2257-66 - PubMed
  40. Curr Mol Med. 2005 Jun;5(4):443-52 - PubMed
  41. mBio. 2010 Jul 20;1(3): - PubMed
  42. Nature. 2009 Jul 2;460(7251):103-7 - PubMed
  43. Nat Immunol. 2011 Jun;12(6):509-17 - PubMed
  44. Mucosal Immunol. 2010 Jul;3(4):361-73 - PubMed
  45. Infect Immun. 2007 Mar;75(3):1424-35 - PubMed
  46. OMICS. 2011 Sep;15(9):533-7 - PubMed
  47. Infect Immun. 2006 Jan;74(1):516-27 - PubMed
  48. J Immunol. 2009 Aug 15;183(4):2407-14 - PubMed
  49. F1000 Med Rep. 2011;3:13 - PubMed
  50. Infect Immun. 2002 Jul;70(7):3759-67 - PubMed
  51. J Infect Dis. 2008 Apr 1;197(7):967-71 - PubMed
  52. Lancet Infect Dis. 2008 Feb;8(2):114-24 - PubMed
  53. J Exp Med. 2005 Sep 5;202(5):597-606 - PubMed

Publication Types